Results 121 to 130 of about 4,295 (215)

Netupitant/palonosetron is effective for preventing chemotherapy-induced nausea and vomiting in high-dose melphalan conditioning before autologous stem cell transplantation: A real-world analysis. [PDF]

Blood Sci
Cao LQ, Dai J, Wang T, Liu BN, Deng DX, Liu Y, Wang YY, Fan QL, Guo RY, Qu Y, Gao YQ, Qi XX, Liu MR, Qi XJ, Feng ZP, Mo XD.   +15 more
europepmc   +1 more source

Palonosetron, a 5-HT3 Receptor Antagonist, Induces G1 Cell Cycle Arrest and Autophagy in Gastric Cancer Cells. [PDF]

Int J Mol Sci
Yoo YC, Lin L, Lee S, Shin YR, Oh JE, Kim NY.   +5 more
europepmc   +1 more source

Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer. [PDF]

Future Oncol
Shin J, Kim JY, Ahn HK, Ahn JS, Park YH.
europepmc   +1 more source

Cardiotoxicity of different 5-HT3 receptor antagonists analyzed using the FAERS database and pharmacokinetic study. [PDF]

Sci Rep
Cai Y, Luo S, Lin S, Huang X, Wang X, Yang L, Xu X, Weng X.   +7 more
europepmc   +1 more source

Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial. [PDF]

BMJ Open
Luo H, Hu Q, Zeng L, Huang Q, Luo Y, Li T, Chen P, Yi C, Gou H.   +8 more
europepmc   +1 more source

Prophylactic use of a combination of palonosetron hydrochloride and dexamethasone to prevent transcatheter arterial chemoembolization-induced nausea and vomiting among patients with hepatocellular carcinoma. [PDF]

Front Med (Lausanne)
Zhang WM, Zheng MJ, Li C, Chen LL, Yu C, Zhou JF, Zheng J.   +6 more
europepmc   +1 more source

Incidence of and risk factors for postoperative nausea and vomiting at a Japanese Cancer Center: first large-scale study in Japan [PDF]

, 2012
MORINO Ryozo, NAGATA Osamu, OZAKI Makoto, YOKOTA Miyuki   +3 more
core   +2 more sources

Effective Use of Olanzapine for Chemotherapy-Induced Nausea and Vomiting in a Patient Receiving Dose-Adjusted Rituximab, Etoposide, Prednisone, Vincristine (Oncovin®), Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report. [PDF]

Cureus
Shimada H, Ohgami M, Kurokawa Y, Tachihara S, Sugaya A.   +4 more
europepmc   +1 more source

Palonosetron

Drugs in R & D, 1999
openaire   +2 more sources

Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial. [PDF]

BMC Med
Zhao Y, Ma Y, Yin T, Qin Z, Liu L, Kong G, Zhang R, Huang Y, Zhang L, Zhao H.   +9 more
europepmc   +1 more source